AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $240K and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $69K to $210K in total in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$240K netNet selling
- CongressSTOCK Act, last 180 days
- $69K to $210K tradedMixed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 5 cutMore cutting
Key stats
Fundamentals Sep 30- Open
- $225.87
- 52-wk high
- $230.49
- High
- $230.49
- 52-wk low
- $138.00
- Low
- $225.51
- Prev close
- $227.60
- Mkt cap
- $33.55B
- P/E
- 40.4x
- Volume
- 1.33M
- Fwd P/E
- 13.9x
- Beta
- 0.17
- P/S
- 3.3x
- P/B
- 1.8x
- Profit margin
- +8.3%
- Op margin
- +25.1%
- ROE
- +4.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BIIB filings
Are insiders buying or selling Biogen Inc (BIIB) stock?
Net selling: insiders sold $240K and bought $0 of BIIB stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $240K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Minor, Lloyd (Director), who sold $240K. The latest filing was on Aug 5, 2026.
Which members of Congress have traded BIIB recently?
Rep. Kevin Hern (R) sold $1K to $15K on Aug 18, 2026, disclosed 14 days later. Rep. Gilbert Cisneros (D) bought $1K to $15K on Jun 5, 2026, disclosed 27 days later. Rep. Maria Elvira Salazar (R) sold $15K to $50K on Jun 2, 2026, disclosed 35 days later. Rep. Maria Elvira Salazar (R) bought $1K to $15K on May 12, 2026, disclosed 27 days later. In total, 3 members disclosed 6 BIIB trades with trade dates in the last 180 days, filed a median 28 days after trading.
How current is this BIIB smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- CI
Citadel
$65.1M
added
Sells/Trims (2)
- P7
Point72
$129.4M
trimmed
- BA
Balyasny
$61.9M
trimmed
What insiders are doing
Sells (1)
- ML
Minor Lloyd
$240K
sold
What Congress is doing
Buys (1)
Sells (2)
How top traders are positioned
No tracked top-trader positions in BIIB right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 18.4% above what analysts expected.
Earnings per share
$3.04 expected
Reports Oct 29, 2026, in 28 days
Estimates as of Oct 1, 2026
EPS expected
$1.44 to $2.67
Revenue expected
26 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.45B | $2.28B | $2.48B | $2.74B |
| Cost of what it sold | $876.6M | $496.3M | $661.0M | $1.18B |
| Gross profit | $1.58B | $1.78B | $1.82B | $1.56B |
| What it spent | ||||
| Research and development | $369.6M | $509.3M | $573.0M | $495.6M |
| Sales and admin | $594.8M | $683.0M | $607.3M | $709.7M |
| Other operating costs | — | $647.7M | $239.1M | $34.0M |
| Total operating expenses | $964.4M | $1.84B | $1.42B | $1.24B |
| What was left | ||||
| Operating profit | $613.8M | -$57.0M | $397.4M | $318.1M |
| Interest on debt | $67.4M | $67.5M | $67.6M | $82.3M |
| Profit before tax | $557.3M | -$211.0M | $377.7M | $132.4M |
| Tax | $90.8M | -$162.6M | $58.2M | $34.9M |
| Net profit | $466.5M | -$48.4M | $319.5M | $97.5M |
| EBITDA | $826.9M | $212.2M | $553.6M | $78.2M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?
Leans bullishSep 30Has Mesoblast (ASX:MSB) Cleared a Key FDA Manufacturing Hurdle for Ryoncil?
NeutralSep 30Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
NeutralSep 30Biogen stock after-hours at EUR 200.20: minus 0.22 percent versus prior close
NeutralSep 29Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
NeutralSep 29NeuroSense Therapeutics Ltd. (NRSN) Stock Price, News, Quote & History
NeutralSep 29How At Home Alzheimer’s Treatment Could Impact Biogen (BIIB) Investors
Leans bullishSep 29Biogen stock at USD 228.69 on September 28, 2026
Leans bullishSep 28
Macro
20 macro signals shaping BIIB right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results